Design of "pseudo-natural product" inhibitors of DNA gyrase

Christopher Marriott¹, Marco Cominetti¹, Andrew Beekman¹, Anthony Maxwell² & Mark Searcey¹

¹School of Pharmacy, University of East Anglia, Norwich Research Park, Norwich, NR4 7TJ, United Kingdom


²Department of Biological Chemistry, John Innes Centre, Norwich Research Park, Norwich, NR4 7UH, United Kingdom

1. Introduction


- Antimicrobial resistance poses a huge threat to society, with the predicted number of deaths owing to resistance estimated to rise from 700,000 in 2014 to 10,000,000 by 2050. New compounds must therefore be found to combat resistance.
- DNA gyrase is an essential topoisomerase enzyme found in bacteria which catalyses negative supercoiling of closed-circular double-stranded DNA.
- Previous work has found that certain members of the simocyclinone class of natural products, found in *Streptomyces* strains present in soil, inhibit the binding of DNA gyrase to DNA.² However, the structures of these natural products make these compounds difficult to synthesise.

2. DNA gyrase

• DNA gyrase is a type IIA topoisomerase enzyme.



- It is the only topoisomerase capable of catalysing the introduction of negative supercoils into bacterial DNA
- Inhibited by the simocyclinones (e.g. SD8) which bind to GyrA




4. Linker design

- Examined use of terminal azidoalkyl acids to replace tetraene and D-olivose regions.
- Azides can react with alkynes to form triazoles via Click chemistry
- Generated a series of alkyl-triazolo linked compounds in silico which were then docked into GyrA

Compound (2) had highest docking score so 10-azidodecanoic acid to be used for future *in silico* design steps.

3. Problems and aims


- SD8 is unable to penetrate cell membranes and is difficult to synthesise
- Aim is to design "pseudo-natural products" based on SD8 in silico and to test these compounds against DNA gyrase and cells



5. In silico hybrid testing

• Libraries of amines (to replace aminocoumarin) and terminal alkynes (to replace angucyclinone) prepared from Aldrich Market Select

Libraries used to generate hybrids which were docked into GyrA, top 5 scorers taken forward for synthesis



Conclusions and Future Work

- DNA gyrase is an essential bacterial enzyme, and so is a good target for novel antimicrobials
- A series of fragments to replace various components of SD8 have been identified in silico to show potential for binding to DNA gyrase
- Synthesis of SD8-fragment hybrids is currently underway, starting with SD8-alkyne hybrids
- Hybrids will then be used in a supercoiling assay to determine activity, following which the best angucuclinone-replacing alkyne will be taken forward to study the aminocoumarin-replacing amines

References and acknowledgements

- 1 J. O'Neill, Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations, 2014.
- 2 J. Schimana, H.-P. Fiedler, I. Groth, R. Submuth, W. Beil, M. Walker and A. Zeeck, J. Antibiot. (Tokyo)., 2000, 53, 779–787.
- 3 M. J. Buttner, M. Schäfer, D. M. Lawson and A. Maxwell, *FEMS Microbiol. Rev.*, 2018, **42**, 100-112 Central image adapted from PDB ID 4CKL

This work was supported by the Biotechnology and Biological Sciences Research Council Norwich Research Park Biosciences Doctoral Training Partnership [Grant number BB/M011216/1]

Biotechnology and

Biotechnology and

Biotechnology and

Biotechnology and

